


[Fig. 1a]


M(KDa)
Control
Mono FacⅦ-ATKAVC
95
72
55
43
Mono FacⅦ-ATKAVC


[Fig. 1b]


Control
FacⅦ-G4SC
95
72
55
43


[Fig. 1c]


FacVII
-ATKAVC
FacVII
-S0DI 149
95
42
55
43


[Fig. 2]


1
2
M
3
4
KDa
200
150
120
100
85
70
60
50
40
30
25
20
15
FacVII-ATKAVC


[Fig. 3]


M
1
2
KDa
230
150
120
100
85
70
60
50
40
30
FacVII-ATKAVC-40 KDA PEG
FacVII-ATKAVC-5 KDA PEG
FacVII-ATKAVC


[Fig. 4a]


kDa
M
1
2
200
150
120
100
85
70
60
50
40
30
FacVIIa-ATKAVC-10k PEG-Fc
Mono FacVIIa-ATKAVC (Heavy Chain)-10k PEG-Fc
Mono Fc
Mono FacVIIa-ATKAVC (Light Chain)

[Fig. 4b]


kDa
1
2
170
130
95
72
55
43
34
26
Anti FVII
kDa
1
2
170
130
95
72
55
43
34
26
Anti human IgG

[Fig. 5]


Absorbance (405nm)
2.0
1.5
1.0
0.5
0.0
0.0001
0.001
0.01
0.1
1
10
100
1000
10000
Concentration (ng/mL)
FVII
FacVII-ATKAVC